The 67 rating InvestorsObserver gives to Crispr Therapeutics AG (CRSP) stock puts it near the top of the Healthcare sector.

In addition to scoring higher than 87 percent of stocks in the Healthcare sector, CRSP’s 67 overall rating means the stock scores better than 67 of all stocks.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style.

Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Crispr Therapeutics AG Stock Today?

Crispr Therapeutics AG (CRSP) stock is lower by -0.59% while the S&P 500 has risen 0.44% as of 9:58 AM on Thursday, Jan 9. CRSP is lower by -$0.37 from the previous closing price of $62.53 on volume of 190,636 shares. Over the past year the S&P 500 is up 26.40% while CRSP has risen 69.23%. CRSP lost -$0.46 per share the over the last 12 months.

To screen for more stocks like CRSP click here.



Source link